A recently evolved class of alternative 3'-terminal exons involved in cell cycle regulation by topoisomerase inhibitors. by Dutertre, Martin et al.
ARTICLE
Received 23 Jul 2013 | Accepted 6 Feb 2014 | Published 28 Feb 2014
A recently evolved class of alternative 30-terminal
exons involved in cell cycle regulation by
topoisomerase inhibitors
Martin Dutertre1,2,3,4,5,*, Fatima Zahra Chakrama1,2,3,4,5,*, Emmanuel Combe1,2,3,4,5,
Franc¸ois-Olivier Desmet1,2,3,4,5, Hussein Mortada1,2,3,4,5, Micaela Polay Espinoza1,2,3,4,5,
Lise Gratadou1,2,3,4,5 & Didier Auboeuf1,2,3,4,5
Alternative 30-terminal exons, which use intronic polyadenylation sites, are generally less
conserved and expressed at lower levels than the last exon of genes. Here we discover a class
of human genes, in which the last exon appeared recently during evolution, and the major
gene product uses an alternative 30-terminal exon corresponding to the ancestral last exon of
the gene. This novel class of alternative 30-terminal exons are downregulated on a large scale
by doxorubicin, a cytostatic drug targeting topoisomerase II, and play a role in cell cycle
regulation, including centromere–kinetochore assembly. The RNA-binding protein HuR/
ELAVL1 is a major regulator of this speciﬁc set of alternative 30-terminal exons. HuR binding to
the alternative 30-terminal exon in the pre-messenger RNA promotes its splicing, and is
reduced by topoisomerase inhibitors. These ﬁndings provide new insights into the evolution,
function and molecular regulation of alternative 30-terminal exons.
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M
ost human genes generate alternative transcripts
through the use of alternative splice sites (90% genes),
promoters (60%) and cleavage-and-polyadenylation
(polyA) sites (60%). Large numbers of alternatively spliced exons
are coordinately regulated during various processes, including
notably cell differentiation and cancer1,2, but studies mainy
focused on cassette exons. Likewise, alternative polyA sites are
widely regulated during several processes, most notably cell
proliferation, where shorter forms are preferentially expressed3–7,
but studies mainly focused on tandem polyA sites, which are
located in the same exon. Thus, little is known about the
regulation of alternative 30 terminal exons, also called alternative
last exons (ALEs), which are found in 43,000 human genes and
correspond to the alternative use of intronic polyA sites in a
splicing-dependent manner7–9.
In contrast with tandem polyA sites, which are located within
30UTRs, intronic polyA sites affect coding regions and give rise to
protein isoforms. In some genes, ALE isoforms have specialized
functions (for example, IgM heavy chain and CT-CGRP genes)8.
However, in general the 30-most exon of a gene (referred to as the
last ALE in this study) is viewed as producing the full-length
isoform, while internal ALEs lead to less abundant and truncated
isoforms, sometimes with dominant-negative properties10–12.
Consistently, intronic polyA sites are much less conserved
between human and murine cDNAs when compared with
30-most polyA sites9,13. Moreover, many cryptic polyA sites lie
in introns and are silenced by a mechanism called
telescripting11,12. ALEs are widely regulated in a tissue-speciﬁc
manner14, but little is known about their dynamic regulation.
Interestingly, internal ALEs are preferentially upregulated during
neuron activation15; a similar regulation was found during cell
proliferation in one study6, but not in another5. Thus, little is
known about ALE regulation on a large scale.
One biological setting where alternative transcripts are
emerging as important new players is the response of cells to
DNA-damaging agents16. These responses involve a partial
repression of gene expression, accompanied by the selective
upregulation of genes involved in DNA repair, cell cycle arrest
and eventually cell death, which is coordinated in a large part by
the p53 transcription factor. Likewise, UV irradiation partially
inhibits cleavage/polyadenylation17, but p53 transcripts escape
such repression18. Several genes involved in the DNA damage
response, such as MDM2 that encodes the main repressor of p53,
are regulated at the splicing level in response to genotoxic
agents16. Recently, UV irradiation and the topoisomerase (TOP) I
inhibitor, camptothecin (CPT), were shown to increase the
inclusion of many cassette exons through an inhibition of
transcription elongation, which gives more time for the
cotranscriptional recognition and inclusion of alternative
exons19–21. CPT also induces skipping of a set of exons, in part
by disrupting the interaction between the EWS and YB-1
proteins22. However, CPT, the only genotoxic agent that was
studied for exonic regulations on a genome-wide scale, can inhibit
transcription elongation independently of DNA damage23.
Moreover, other types of alternative exons such as ALEs were
not examined in these studies. Interestingly, a recent study in
yeast showed that DNA damage can affect polyA site use in many
genes24. Thus, additional large-scale analyses of the effects of
genotoxic agents on alternative transcripts are needed.
Doxorubicin (DOXO), the main drug used in breast cancer
chemotherapy, is a TOP-II inhibitor that induces double-strand
DNA breaks but does not otherwise inhibit transcription
elongation23. A few cases of splicing regulation by TOP-II
inhibitors were previously reported22,25–27. Here using a genome-
wide approach, we show that ALEs are the main type of exons
regulated by acute DOXO treatment in a breast cancer cell line.
Given the high prevalence and highly speciﬁc pattern of ALE
regulation by DOXO, we then determine the functional impact
and molecular mechanism of this regulation. Our ﬁndings
identify a class of evolutionarily recent ALEs that are regulated
on a large scale by DOXO, identify the RNA-binding protein
HuR/ELAVL1 as a regulator of ALE maturation in response to
TOP inhibitors, and implicate ALEs in cell cycle regulation and
chemotherapy.
Results
ALEs are a major type of exons regulated by TOP inhibitors.
To identify alternative exons regulated by DOXO in the MCF-7
breast cancer cell line, we used pan-genomic exon-arrays. We also
compared the effects of DOXO and CPT, which we analysed in
the same cell line using the same technology22. Drug treatments
were done for only 6 h to identify regulations that are not a
consequence of toxicity. Exon-array data were analysed using the
splicing index method followed by manual curation. We
identiﬁed 248 exons regulated by DOXO by 41.8-fold
(Student’s paired t-test, Po0.05; Supplementary Data 1). By
RT-PCR analysis we validated 37 exonic regulations (validation
rate of 62%; Fig. 1e and Supplementary Fig. 1). Meanwhile, 333
genes were regulated at the global level by 41.8-fold (Student’s
paired t-test, Po0.05; Supplementary Data 2). Most of the exonic
regulations we identiﬁed did not occur in globally regulated genes
(Fig. 1a and Supplementary Fig. 1e). However, both sets were
enriched in genes involved in cell cycle (Table 1), suggesting that
exon regulations, like global gene regulations, may play a role in
cellular responses to DOXO (see below).
We then compared the large-scale patterns of exon regulation
by DOXO and CPT, using the identiﬁed top-lists of regulated
exons for each drug (Supplementary Data 1 and 3). Interestingly,
ALEs were the most prominent category of exons regulated by
DOXO, and a major category of exons regulated by CPT (almost
as frequent as cassette exons; Fig. 1b). Regulations of cassette
exons may be over-estimated because there are many more
cassette exons than ALEs in transcript databases and exon-arrays.
In addition, the splicing index method was originally designed for
cassette exons and may not be optimal for mutually exclusive
exons such as ALEs. Using an algorithm speciﬁcally comparing
the regulation of internal ALEs to their following exon, we
identiﬁed additional ALEs regulated by DOXO (Supplementary
Data 4). In total, we identiﬁed 100 genes regulated by DOXO at
the level of ALEs (both ‘skipped ALEs’ and ‘composite ALEs’; see
methods). Extensive RT-PCR validations are shown in Fig. 1e and
Supplementary Fig. 1c,d. Thus, ALEs are a major category of
alternative exons regulated by both TOP-I and TOP-II inhibitors.
DOXO preferentially represses internal ALEs. As expected from
previous studies and from its ability to inhibit transcription
elongation20–22, CPT favored inclusion more often than exclusion
of cassette exons (Fig. 1c). Likewise, CPT favored the expression
of the internal ALE slightly more often than the last ALE (56
versus 44% cases; Fig. 1d). On the other hand, strikingly, DOXO
favored the exclusion of cassette exons in 82% cases (Fig. 1c),
which is signiﬁcantly more often than CPT (Po4.10 4, test of
proportions). Likewise, DOXO favored the expression of the last
ALE in 90% of cases (Fig. 1d), which is signiﬁcantly more often
than CPT (Po6.10 7, test of proportions). The CPT-speciﬁc
effects will be discussed below (see Discussion). Altogether,
internal ALE repression appears to be the main exonic effect of
DOXO, and is also a highly prevalent effect of CPT (Fig. 1b,d).
We validated 23 such regulations by RT-PCR for DOXO (Fig. 1e
and Supplementary Fig. 1c,d). We also validated by RT-PCR
several cases of internal ALE repression that were predicted to
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be induced by both drugs (Supplementary Fig. 1d and
Supplementary Data 5). For example, the CENPN gene
generates CENPN-pA12 transcripts ending in exon 12 (E12),
and CENPN-pA13 transcripts skipping E12 and ending in
E13 (Fig. 1f). Competitive RT–PCR analysis indicates that
CENPN-pA12 is the major isoform in untreated cells, whereas
CENPN-pA13 is the major isoform after DOXO or CPT
treatment for 6 h (Fig. 1g). Quantitative RT-PCR analysis
indicates that DOXO and CPT increase the CENPN-pA13/
CENPN-pA12 isoform ratio by 4.3- and 17.4-fold, respectively,
by decreasing CENPN-pA12 while increasing CENPN-pA13
levels (Fig. 1h,i). Meanwhile, total CENPN mRNA level was not
affected by DOXO and only moderately decreased by CPT
(Supplementary Fig. 2a). The regulation of ALE isoforms by
DOXO and CPT was veriﬁed at later time points (with stronger
effects at 24 h) and in another breast cancer cell line
(Supplementary Fig. 2b–e).
DOXO represses internal ALEs corresponding to major isoforms.
Internal ALEs are often considered to correspond to low-abundance
truncated variants, and last ALEs to major full-length isoforms10–12.
However, we found that DOXO-repressed internal ALEs
correspond to highly expressed isoforms. Indeed, RT–PCR
analysis of untreated cells detected higher levels of the DOXO-
repressed internal ALE isoform than the last-ALE isoform in 9 out
of 11 tested genes (Figs 1g and 2a). Consistently, in transcript
databases, the fraction of transcripts ending at the internal ALE is
higher for genes where DOXO represses the internal ALE, when
compared with other genes with ALEs in the genome (Fig. 2b).
Moreover, exon-array data in untreated cells indicated that gene-
normalized expression was lower in the case of DOXO-induced
last ALEs, when compared with other last ALEs in the genome
(Fig. 2c). Thus, DOXO-repressed internal ALEs correspond to
highly expressed, often major isoforms (Fig. 2a), whereas for most
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Figure 1 | Repression of internal ALEs is a major type of exon regulation by DOXO. (a) Venn diagram of genes regulated by DOXO at the exon or global
levels. (b) Classiﬁcation of alternative exons regulated by DOXO or CPT. ALE, alternative last exons; ASE, cassette exons; ASS, alternative splice sites;
IR, intron retention; AFE, alternative ﬁrst exons (alternative promoters); APA, tandem polyA sites; Uncl., unclassiﬁed. (c) Effects of DOXO and CPT on
cassette exons (exclusion or inclusion). (d) Effects of DOXO and CPT on the internal ALE/last ALE ratio. In (c and d), a test of proportions shows that
DOXO more often induces exon exclusion (or last-ALE induction) than CPT (Po4.104 and Po6.10 7, respectively). (e) RT–PCR validation of ALE
regulation by DOXO. Isoforms are designated by ‘pA’ and exon number. The location of size markers (in bp) is indicated. Representative data of
three independent experiments are shown. (f) Schematics of the CENPN gene. Exons and introns are represented by rectangles and lines, respectively. pA,
polyA site. (g–i) Regulation of ALEs by DOXO and CPT in the CENPN gene. Analysis by RT-PCR (g) and RT-qPCR (h,i). Data represent the mean±s.e.m. of
16 (h) or 5 (i) independent experiments. All drug treatments were done for 6 h. CTRL, vehicle-treated cells.
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DOXO-repressed internal ALEs resemble more last exons of
genes than average internal ALEs, not only according to
expression level but also to exon length, as they were on average
longer than other internal ALEs in the human genome, like last
ALEs (Fig. 2d). Consistently, DOXO-repressed internal ALEs
often correspond to ancestrally last exons of genes. Indeed, while
for randomly selected human genes, the internal ALE rarely
corresponds to the last exon of the gene in non-mammalian
vertebrates (Fig. 2e, ‘genome’), DOXO-repressed internal ALEs
correspond to the ancestral last exon of the gene in B50% cases
(Fig. 2e, ‘DOXO-regulated’). The novel last ALE appeared either
in mammals (in most cases) or in primates (example in Fig. 2f).
Thus, DOXO-repressed internal ALEs are strongly enriched in a
particular class of internal ALEs that are highly expressed and
correspond to ancestrally last exons and therefore full-length
isoforms. Further supporting this notion, in several cases
(including UHRF1BP1; Supplementary Fig. 1f) the last-ALE
isoform bears a premature stop codon, which is known to induce
nonsense-mediated mRNA decay (NMD) instead of productive
translation. As NMD isoforms are expected to be expressed at low
levels even after splicing induction, we re-analysed our exon-array
data with relaxed stringency on exon expression, and found
16 additional genes with DOXO-induced last ALEs of the NMD
type. Altogether, our data indicate that DOXO typically represses
internal ALEs that encode abundant (often major) and ancestrally
full-length isoforms, suggesting that this regulation may have a
functional impact.
DOXO-regulated ALEs play a role in cell cycle regulation.
As already mentioned, DOXO-regulated exons were enriched in
genes involved in DNA damage response (including DNA repair)
and cell cycle, more speciﬁcally M phase-associated processes (for
example, chromosome and centromere–kinetochore–spindle
network; Table 1). Similar functions were enriched when focusing
on DOXO-regulated ALEs (Table 1). Enrichment in mitosis-
related genes is also found in globally regulated genes (Table 1)
and is highly relevant because the inhibition of cell cycle pro-
gression (an important aspect of the DNA damage response) in
response to DOXO mainly occurs at the level of G2/M (ref. 28).
To test the role of DOXO-regulated ALEs in cell cycle
regulation, we focused on the CENPN gene that is involved in
centromere–kinetochore assembly and mitosis29. Assembly of the
CCAN complex (Constitutive Centromere Associated Network)
is directed by a centromere-speciﬁc histone variant called CENPA
that recruits CENPN through interaction with CENPN
N-terminal region (Fig. 3a and Supplementary Fig. 3a). In turn,
CENPN recruits several other CCAN components (including
CENPH) through interaction of its C-terminal region with
CENPL30. However, only the CENPN-pA12 isoform,
corresponding to the internal ALE and the ancestral isoform,
has been studied. Interestingly, half of the CENPL-interacting
region that was mapped30 is absent in the CENPN-pA13 isoform.
To test whether the CENPN-pA13 isoform is unable to promote
CCAN assembly, we developed siRNAs targeting either both
CENPN isoforms or each isoform selectively (Fig. 3b and
Supplementary Fig. 3b).
In untreated cells, CENPH colocalized with CENPA nuclear
foci that mark centromeres, and this colocalization was strongly
decreased by siRNAs targeting either both CENPN isoforms
or CENPN-pA12 only (Fig. 3c), as expected from previous
studies29–31. In contrast, CENPH colocalization with CENPA was
not affected by several siRNAs targeting the CENPN-pA13
isoform selectively (Fig. 3c and Supplementary Fig. 3c).
Moreover, CENPN isoforms exhibited different subcellular
localization. Indeed, using GFP-CENPN constructs as in
previous studies, the CENPN-pA12 isoform exhibited punctate
staining strongly colocalizing with both CENPA and CENPH
(Fig. 3d and Supplementary Fig. 3d, ‘GFP-N12’), in addition to
some diffuse staining as previously reported30,32. In contrast,
the CENPN-pA13 isoform did not colocalize with CENPA or
CENPH (Fig. 3d and Supplementary Fig. 3d, ‘GFP-N13’),
indicating a defect in centromere localization. This is consistent
with the fact that CENPN association with centromeres is
stabilized by its C-terminal domain (Supplementary Fig. 3d,
‘GFP-N DC-ter’)30–32.
Altogether, our data indicate that DOXO represses the
expression of the CENPN-pA12 isoform that mediates
centromere–kinetochore assembly, and increases the CENPN-
pA13 isoform that is not competent for this activity. Consistently,
DOXO disrupted (in 55% cells) the colocalization of CENPH
with CENPA without affecting CENPA staining (Fig. 3e,f),
similarly to CENPN-pA12 depletion. Interestingly, CENPN-pA13
depletion partially prevented the disruption of CENPH foci by
DOXO (Fig. 3e,f and Supplementary Fig. 3e), suggesting a role of
the CENPN-pA13 isoform in the presence of DOXO. These data
reveal that DOXO disrupts CCAN assembly, at least in part
through CENPN isoform switching.
Furthermore, CENPN-pA12 depletion increased the accumu-
lation of MCF-7 cells in G2/M in the presence of DOXO at a dose
and time point where DOXO had only a modest effect by itself
(Fig. 3g). This effect is consistent with the role of CENPN in
mitosis through kinetochore assembly29. Conversely, the effect of
DOXO on G2/M was partially prevented by CENPN-pA13
depletion, and this was more evident when using a dose of DOXO
that has a stronger effect on G2/M accumulation (Fig. 3g and
Supplementary Fig. 3f). Altogether, our data suggest that the
CENPN-pA13 isoform does not promote CCAN assembly and






333 genes globally regulated by DOXO
Cell division 13 5.90E03 2.5
Mitotic cell cycle 14 1.40E02 2.2
Mitosis 9 4.00E02 2.3







248 genes with exons regulated by DOXO
Response to DNA damage
stimulus
18 1.20E05 3.5
DNA repair 14 1.30E04 3.6
Cell cycle 23 8.00E04 2.2
M phase 11 1.40E02 2.5
Chromosome 19 5.50E06 3.6
Chromosome, centromeric region 8 5.70E04 5.6
Kinetochore 6 1.90E03 6.7
Spindle 7 7.00E03 4.1
100 genes with ALEs regulated by DOXO
Response to DNA damage
stimulus
8 3.10E03 4.1
Cell cycle 11 6.30E03 2.7
Chromosome 8 5.60E03 3.6
*One-tail Fisher exact probability value used for gene-enrichment analysis, using the DAVID
software and the human genome as a reference.
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G2/M progression, but may inhibit these processes in DOXO-
treated cells (Fig. 3c–g and Supplementary Fig. 3). Thus,
DOXO-induced switch of CENPN isoforms may play a role in
the regulation of centromere–kinetochore assembly and cell cycle
by DOXO.
TOP inhibitors repress internal ALEs at the pre-mRNA level.
Given the high prevalence and functional relevance of internal
ALE repression by DOXO, we then investigated the underlying
molecular mechanism, mainly focusing on the CENPN gene. As
CPT also represses internal ALEs in a large set of genes (Fig. 1d),
including CENPN (Fig. 1g), the effects of CPT were analysed in
parallel to potentially identify mechanisms of internal ALE
repression shared by TOP inhibitors. The differential regulation
of ALE isoform expression could be due either to differential
mRNA stability, because 30UTRs can regulate cytoplasmic mRNA
stability, or to the regulation of nuclear pre-mRNA maturation, as
ALE selection depends on an interplay between alternative spli-
cing and polyadenylation (Fig. 4a). Several data indicate that ALE
isoform regulation by DOXO and CPT is mediated at least in part
at the level of nuclear maturation. First, DOXO and CPT induced
a switch of CENPN isoforms (Fig. 1h,i). Second and more
importantly, the regulation was observed in the nucleus (Fig. 4b).
Third, actinomycin D prevented the effect of DOXO on CENPN
isoform ratio, indicating a requirement for on-going transcrip-
tion, but did not affect the CENPN isoform ratio by itself, sug-
gesting no differential isoform stability (Fig. 4c). Fourth, DOXO
and CPT strongly increased the spliced to unspliced ratio of
CENPN exon E13 in nuclear RNA fractions, without increasing
the spliced to unspliced ratio of E12 (Fig. 4d and Supplementary
Fig. 2f). Fifth, DOXO and CPT increased the use of the E13 polyA
site relative to the E12 polyA site, as shown by quantifying in
nuclear RNA fractions, the transcripts upstream and downstream
of each polyA site18 (Supplementary Fig. 2g). In addition to
CENPN, we also veriﬁed for two other genes that the regulation of
ALE isoforms by DOXO was observed in the nucleus
(Supplementary Fig. 2h). However, we cannot exclude that for
some other genes, or in addition to nuclear effects, DOXO might
also affect cytoplasmic mRNA isoform stability, for example
through miRNAs.
As cleavage/polyadenylation is connected to transcription
termination, and polyA sites induce RNA polymerase II (Pol-II)
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Figure 2 | DOXO represses internal ALEs corresponding to major isoforms. (a) Competitive RT–PCR ampliﬁcation of internal and last-ALE isoforms in
untreated cells. Arrowheads indicate internal ALE isoforms. Last-ALE isoforms are often not detected, although they can be ampliﬁed separately as shown
in Fig. 1e. The location of size markers (in bp) is indicated. Representative data of three independent experiments are shown. (b) Percent of transcripts from
Genbank that end at the internal ALE rather than the last ALE, in genes whose ALEs are regulated by DOXO (internal ALE repression) or not. Shown are
medians±s.e.m. of 50 and 1,545 genes, respectively (see Methods). (c) Gene-normalized expression of last ALEs that are regulated by DOXO
(upregulation relative to internal ALE) or not. Exon-array data from untreated cells. Shown are medians±s.e.m. of 38 and 304 genes, respectively (see
methods). (d) Boxplot of exon length, comparing DOXO-repressed internal ALEs (n¼48) with internal and last ALEs in the genome (n¼ 2,216). Shown are
the median, the ﬁrst and third quartiles, 1.5 times the interquartile range (whiskers) and outliers. (e) Conservation of human ALEs in non-mammalian
vertebrates. Comparison of DOXO-regulated ALEs and randomly selected control ALEs (n¼ 55 and 32, respectively; see Methods). (f) Multi-alignment
of the CENPN gene sequence in various Vertebrates (screenshot from the UCSC genome browser; green areas are conserved regions). *Po5.10 2;
**Po5.104 and ***Po2.10 5. Wilcoxon rank sum test (b–d) or test of proportions (e).
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Figure 3 | DOXO-regulated ALEs play a role in centromere–kinetochore assembly and cell cycle. (a) Schematics of the centromere–kinetochore network.
(b) RT–qPCR validation of siRNAs targeting either both CENPN isoforms or each isoform selectively (48-hour transfection). Data represent the
mean±s.e.m. of four independent experiments. (c) Immunoﬂuorescence of CENPA and CENPH following transfection of siRNAs targeting CENPN isoforms
for 48 h. CENPH data are quantiﬁed on the bottom panel. Data represent the mean±s.e.m. of ﬁve independent experiments. (d) (Immuno-) ﬂuorescence
of GFP and CENPH following transfection of GFP-CENPN isoform constructs for 24 h. Representative data of four independent experiments are shown.
(e,f) Immunoﬂuorescence of CENPA and CENPH following transfection with siCTRL or si13 for 48 h, including 19 h with or without DOXO. Data are
quantiﬁed in (f). Data represent the mean±s.e.m. of three independent experiments. (g) FACS analysis of cell cycle (G2M:S ratio) following transfection of
siRNAs targeting CENPN isoforms for 48 h, including 19 h with or without DOXO. Data represent the mean±s.e.m. of seven independent experiments.
*Po2.10 2 (Student’s paired t-test). NS, not signiﬁcant. siCTRL, siRNA targeting luciferase; siT, siRNA targeting both CENPN isoforms. In (c–e), scale bars
represent 5mm.
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Pol-II dynamics on the CENPN gene by chromatin immuno-
precipitation. In untreated cells, we observed peaks of Pol-II levels
around both E12 and E13 polyA sites compared with matched
upstream regions (Fig. 4e), which is consistent with pauses of Pol-
II occurring around each polyA site. DOXO and CPT strongly
reduced the peak of Pol-II over the E12 polyA site compared with
an upstream region (Fig. 4f,g), suggesting an inhibition of the
recognition of this polyA site (or its ability to induce pausing) and
reﬂecting the decrease of the CENPN-pA12 mRNA. In contrast,
DOXO and CPT did not reduce the peak of Pol-II over the E13
polyA site (Fig. 4h). Altogether, these data suggest that DOXO
and CPT inhibit the cotranscriptional recognition of the internal
ALE in the CENPN gene.
HuR/ELAVL1 mediates internal ALE repression by TOP
inhibitors. Looking for splicing- and polyadenylation-regulatory
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Figure 4 | TOP inhibitors affect ALE isoform expression at the level of pre-mRNA maturation. (a) Schematics of the CENPN gene. Exons and introns
are represented by rectangles and lines, respectively. Amplicons used in e–h are shown. pA, polyA site. (b) RT–PCR analysis of CENPN isoform
expression in nuclear RNA following drug treatment as indicated. The location of size markers (in bp) is indicated. Representative data of ﬁve independent
experiments are shown. (c) RT–qPCR analysis of CENPN isoform ratio following treatment with DOXO and/or actinomycin D (‘AD’). Data represent
the mean±s.e.m. of four independent experiments. (d) RT–qPCR analysis of nuclear RNA for the effects of drugs on the ratio of spliced to unspliced
transcripts for each ALE of CENPN. Controls are set to 1. Data represent the mean±s.e.m. of four independent experiments. (e–h) Chromatin
immunoprecipitation with an anti-Pol-II antibody followed by qPCR analysis of the indicated regions in the CENPN gene. Drug treatments are indicated.
Note that DOXO and CPT had little effect on Pol-II levels at the level of i11-e12. Data represent the mean±s.e.m. of four independent experiments. All drug
treatments were done for 6 h.
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we found B20 factors whose expression anti-correlated with the
inclusion rate of DOXO-stimulated last ALEs across a panel of
human cell lines in a publicly available exon-array data set
(ENCODE34; Supplementary Data 6). Two of these factors were
previously involved in DNA damage responses. The ﬁrst one,
BARD1, inhibits cleavage/polydenylation in response to UV
irradiation17,35. As expected from the anti-correlation data, the
CENPN-pA13/CENPN-pA12 ratio was increased following
BARD1 depletion (Supplementary Fig. 4a,b). In addition,
BARD1 depletion decreased the fold-effect of DOXO on the
CENPN isoform ratio, but only by half (Supplementary Fig. 4c),
and in fact, the isoform ratio measured in the presence of DOXO
was not decreased by BARD1 depletion (Supplementary Fig. 4d).
Thus, the effect of DOXO on CENPN ALEs appears to be only
partially mediated by BARD1.
The second factor, HuR/ELAVL1, is an RNA-binding protein
that has long been involved in the regulation of cytoplasmic
mRNA stability and translation in response to DNA damage
(reviewed by Gorospe36) and more recently in pre-mRNA
splicing and polyA site use in the nucleus37–42. As expected
from the anti-correlation data, the depletion of HuR using a
speciﬁc siRNA in MCF-7 cells (Fig. 5a) led to an increase in the
CENPN-pA13/CENPN-pA12 mRNA ratio (Fig. 5b). This result
was conﬁrmed using a second siRNA (Supplementary Fig. 5a).
Importantly, HuR depletion impacted the CENPN isoform ratio
in the nucleus (Fig. 5c) and increased the spliced to unspliced
ratio of E13 but not E12 (Fig. 5d). Thus, HuR depletion affects
CENPN ALE maturation in a similar way to DOXO and CPT
(Fig. 4b,d). We then tested whether HuR associates with CENPN
transcripts before ALE maturation has been completed, and
whether this association is decreased by DOXO and CPT. For
this, we peformed RNA-immunoprecipitation using an anti-HuR
antibody (3A2) followed by RT-qPCR. As expected from previous
studies and validating our assay, HuR was found associated with
c-fos but not gapdh transcripts (Fig. 5e)37. Importantly, HuR was
associated with CENPN pre-mRNA containing the uncleaved E12
polyA site, and both DOXO and CPT treatments decreased this
association (Fig. 5e,f, ‘uncl. pA12’). The effect of CPT on HuR
association with CENPN pre-mRNA containing uncleaved pA12
was about twofold stronger than the effect of DOXO, as in the
case of CENPN-pA12 mRNA expression regulation (Fig. 1h,i).
We also detected HuR association with spliced CENPN-pA12
transcripts, but this association was not decreased by DOXO and
CPT (Fig. 5e,f, ‘spliced E12’). Thus, DOXO and CPT inhibit HuR
association with CENPN pre-mRNA, but not mature mRNA, in
line with their effect on ALE maturation. Altogether, our data
suggest that DOXO and CPT may regulate CENPN ALEs by
inhibiting the association of HuR with CENPN pre-mRNA.
In the entire CENPN gene, only two HuR-binding sites were
consistently found by two independent CLIP-seq studies that
mapped HuR-binding sites on a genome-wide scale37,38.
Remarkably, both of these sites lie in E12, and additional
(potentially weaker) binding sites are also found in E12 by each
CLIP-seq study (Supplementary Fig. 6). To assess whether HuR
may play a wider role in internal ALE repression by DOXO, we
then analysed HuR-binding sites in the set of DOXO-regulated
ALEs. HuR binding sites were found inB30–50% (depending on
data set) of DOXO-repressed internal ALEs, as opposed to only
B10% of non-regulated internal ALEs (Fig. 5g). This enrichment
was still observed after normalization against exon size
(Supplementary Fig. 5b) and was striking given that both HuR
CLIP-seq analyses were done in different cell lines than our study
on DOXO. The enrichment of HuR-binding sites was particularly
strong for DOXO-repressed internal ALEs corresponding to
ancestral last exons (Fig. 5h, ‘only internal ALE conserved’), thus
identifying HuR binding as a determinant of the preferential
repression of conserved internal ALEs by DOXO (Figs 1d and 2e).
We also validated for two other genes that HuR depletion favored
the nuclear production of the last ALE like DOXO
(Supplementary Fig. 5c,d). Finally, as expected from a previous
study43, DOXO induced partial relocalization of HuR from the
nucleus to the cytoplasm (Fig. 5i and Supplementary Fig. 5e).
Altogether, our ﬁndings that DOXO induces dissociation of HuR
from DOXO-repressed internal ALE within pre-mRNA (Fig. 5f),
HuR depletion mimics the effect of DOXO on ALE splicing
(Fig. 5b–d) and HuR-binding sites are enriched in DOXO-
repressed internal ALEs (Fig. 5g,h) suggest that HuR mediates the
repression of at least a subset of internal ALEs in response to
DOXO (Fig. 5j).
Discussion
ALEs were identiﬁed in many human genes, but little is known
about their regulation on a large scale. The regulation of ALEs
depends on an interplay between pre-mRNA splicing and other
nuclear processes, especially cleavage/polyadenylation and tran-
scription termination. In this study, we show that ALEs are a
major type of exons regulated by TOP inhibitors; DOXO
represses a particular subset of internal ALEs corresponding to
ancestrally last exons; this effect is mediated at least in part by
HuR acting at the level of pre-mRNA maturation, and DOXO-
regulated ALEs are involved in cell cycle regulation. These data
shed new light on the regulation and function of ALEs, and
identify ALEs as a novel layer of exon regulation by genotoxic
agents.
While internal ALEs often correspond to low-abundance,
poorly conserved and truncated isoforms9–13 (Fig. 2b,e), the set of
internal ALEs repressed by DOXO is strongly enriched in a
particular class identiﬁed herein as highly expressed, ancestrally
last exons of genes (Fig. 2a,b,e). It would be interesting to identify
this class of ALEs on a genome-wide scale to further determine
their structural and functional properties. For example, they tend
to occur in the penultimate exon of genes (Supplementary
Fig. 5f). There may exist a selection pressure to maintain high
expression of these ancestrally full-length isoforms. Their high
expression may be due in part to relatively high 30-splice site
strength (Supplementary Fig. 5g) and/or to HuR-binding sites
(Fig. 5h).
Indeed, our ﬁndings suggest that DOXO-repressed internal
ALEs depend on HuR for inclusion in mature mRNA (Fig. 5 and
Supplementary Fig. 5a–c). Consistently, genome-wide mapping of
HuR-binding sites revealed its binding to many pre-mRNAs, and
HuR can regulate both splicing and polyA site use37–42. The
conﬁguration of HuR-binding sites in CENPN exon 12, with two
centrally located strong binding sites and additional (potentially
weaker) binding sites along the exon (Supplementary Fig. 6), is
consistent with the ability of HuR to cooperatively bind at
multiple sites along RNA and to multimerize44, which could
conceivably favour the recognition of this large ALE exon by
various mechanisms. For example, it might bring closer the
30-splice site and the polyA site. Alternatively, HuR binding was
proposed to stabilize pre-mRNA37, and this would give more time
for cotranscriptional splicing and polyadenylation of the internal
ALE. Also interesting in this context, RNA-bound HuR
can induce chromatin modiﬁcations around exons, thereby
inﬂuencing cotranscriptional splicing40. Alternatively, HuR
could locally regulate the 30-splice site or the polyA site of exon
12, because one CLIP-seq study found HuR-binding sites in their
vicinity (Supplementary Fig. 6), and HuR can bind or affect the
recruitment of splicing and polyadenylation factors to exons and
polyA sites, respectively39,41,42. HuR dissociation from CENPN
pre-mRNA in response to DOXO and CPT is consistent with
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Figure 5 | Internal ALE repression by TOP inhibitors is mediated by HuR dissociation from pre-mRNA. (a) Western blot showing HuR depletion
following siRNA transfection for 48 h. siCTRL, siRNA targeting luciferase. Representative data of three independent experiments are shown. (b–d) RT–qPCR
analysis of CENPN transcripts following siRNA transfection for 48 h. Shown is the fold-effect of the siRNA targeting HuR on CENPN isoforms in whole cells
(b) and nuclear fraction (c), and on the nuclear ratio of spliced to unspliced transcripts for each ALE (d). Data represent the mean±s.e.m. of three
independent experiments. (e,f) RT–qPCR analysis on the indicated transcripts (see text) following RNA immunoprecipitation using an anti-HuR antibody
(3A2) or control immunoglobulins (Ig). In (f), effects of drugs (6 h) on HuR association with CENPN transcripts (controls are set to 100). Data represent
the mean±s.e.m. of three independent experiments. (g,h), Enrichment of HuR-binding sites in DOXO-repressed internal ALEs, compared with other
internal ALEs in the genome. Two indicated data sets were analysed. *Po5.10 2 and ***Po5.108. Test of proportions, comparing DOXO-regulated and
genome-wide internal ALEs (n¼62 and 2,098, respectively). (i) Effect of DOXO treatment for 6 h on HuR protein localization by immunoﬂuorescence
using the 3A2 antibody. Representative data of four independent experiments are shown. Scale bar, 5 mm. (j) Model of ALE regulation by DOXO
through HuR. DOXO preferentially represses splicing of conserved internal ALEs by inducing HuR dissociation from pre-mRNA. CPT can also repress
internal ALEs by the same mechanism. Exons and introns are represented by rectangles and lines, respectively. pA, polyA site.
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previous evidence that HuR binding to RNA is affected by DNA
damage45–47. HuR is phosphorylated by several protein kinases
mediating DNA damage signalling, including Chk2, p38/MAPK,
PKC and Cdk146. Furthermore, HuR dissociation from pre-
mRNA in response to DOXO may reﬂect its partial relocalization
from nucleus to cytoplasm in response to DNA damage
(Fig. 5i)43,48,49. Altogether, we propose the following model
(Fig. 5j). Internal ALEs in a subset of human pre-mRNAs depend
on HuR association for inclusion in mature mRNA. In response
to DNA damage, this association is inhibited, thereby decreasing
the production of speciﬁc isoforms (for example, CENPN-pA12).
Interestingly, in addition to CENPN that is involved in G2/M,
DOXO and HuR also regulate ALEs in the KIF1B gene
that regulates G2/M and apoptosis, and in the MBD1 gene
involved in DNA damage checkpoint activation (Supplementary
Fig. 5c,d)50,51. Meanwhile, HuR relocates to the cytoplasm, where
it regulates the stability and translation of various mRNAs
involved in proliferation and apoptosis through binding to
30UTRs36,47. Thus, cell responses to DNA damage may involve
the coordinated regulation of both nuclear and cytoplasmic sets
of transcripts by HuR.
Large-scale regulation of alternative polyadenylation and
splicing are increasingly involved in cellular processes, including
proliferation and genotoxic responses, respectively1–8,16,19–21. In
this context, our data provide several advances. First, with regard
to the recent ﬁnding that alternative splicing is coordinately
regulated by cell cycle factors52, we identify a set of genes
involved in M phase, more speciﬁcally the centromere–
kinetochore–spindle network, which are regulated at the
splicing and/or polyadenylation level by DOXO (Table 1). As
several splicing factors are regulated during M phase53, it will be
interesting to determine whether these pre-mRNA maturation
events are regulated during the cell cycle. Moreover, our data
reveal that DOXO disrupts the CCAN complex, at least in part
through the regulation of CENPN ALE isoform expression
(Fig. 3); this regulation adds up to the direct role of TOP-II at
centromeres54. More generally, our data and the recent ﬁnding of
CENPE splicing regulation55 raise the possibility that the tight
regulation of CCAN and kinetochore assembly during the cell
cycle could be mediated in part at the level of pre-mRNA
maturation.
Second, while the role of ALEs and intronic polyA sites in
cellular processes is only emerging11,15, with different patterns of
regulation associated with proliferation depending on cell
models5,6, our data establish a role of ALE regulation in cell
responses to TOP inhibitors. Interestingly, the preferential
repression of intragenic polyA sites by DOXO is reminiscent of
the recent ﬁnding that a UV mimetic reduces the use of internal
polyA sites in many yeast genes24. However, there are several
major differences between the two observed phenomenons: most
genes in yeast do not have introns; UV affects polyA sites in 35%
of yeast genes, in contrast with the high speciﬁcity of DOXO
effects in human cells toward evolutionarily recent last ALEs;
ﬁnally, while UV inhibits cleavage/polyadenylation in both
yeast24 and human cells (through BARD1 binding to the core
cleavage/polyadenylation factor CstF)17,35, CENPN ALE
regulation by DOXO does not appear to be primarily mediated
by BARD1 and CstF (Supplementary Fig. 4). However, our data
do not exclude a potential contribution of CstF or other core
cleavage/polyadenylation factors to the effects of DOXO on ALEs.
Another mechanism regulating intronic polyA sites is repression
by the U1 snRNA, but again, DOXO effects on ALEs were much
more speciﬁc than those of U111,12. Finally, as hnRNP H/F
proteins protect p53 transcripts against polyA repression by DNA
damage18, they might also contribute to ALE regulation.
Altogether, while our data reveal a mechanism of internal ALE
repression by TOP inhibitors through HuR, it is likely that DNA-
damaging agents can regulate other polyA sites by other
mechanisms.
Third, our ﬁndings reveal both similar and different patterns of
exon regulation by different genotoxic agents. The relative
inability of DOXO to favour inclusion of cassette exons and
internal ALEs (Fig. 1c,d) likely stems from its lack of inhibition of
transcription elongation23, which mediates exon inclusion in
response to CPT and UV19,21,56. Cassette-exon skipping and
internal ALE repression are frequently induced by both DOXO
and CPT22 (Fig. 1c,d), suggesting a regulation by DNA damage
signalling or topoisomerases themselves. In addition to splicing
regulations mediated by the EWS protein and targeting several
key effectors of the DNA damage response22,57, ALE regulation
mediated by HuR and targeting several genes involved in DNA
damage response and cell cycle (for example, CENPN, KIF1B and
MBD1) appears as a novel pathway of regulation of pre-mRNA
maturation mediating genotoxic stress responses. Other such
pathways likely remain to be identiﬁed, because other splicing
factors are affected by DNA-damaging agents16. Characterization
of these pathways should help understand cell responses to
different classes of genotoxic agents.
Finally, this study identiﬁes a group of evolutionarily recent last
ALEs that are induced by genotoxic agents. The low expression of
these novel ALEs in the absence of stress is consistent with the
lower expression of nonconserved polyA sites compared with
conserved ones13. Some of the DOXO-induced last ALEs are
potential NMD targets or disrupt functional domains (for
example, CENPN-pA13), suggesting that switching to the last
ALE may serve to downregulate the functional ancestral isoform
encoded by the internal ALE. However, CENPN-pA13 isoform
depletion partially prevents CCAN disruption and G2/M block
that are induced by DOXO (Fig. 3e,f and Supplementary Fig. 3e,f),
suggesting a (potentially dominant-negative) role for this isoform
in the presence of DOXO. The observation that CENPA and
CENPN but not other CENP proteins are recruited to DNA
breaks in response to radiations58 raises the possibility that the
CENPN-pA13 isoform might prevent kinetochore assembly at
DNA breaks. More generally, it is tempting to speculate that the
recent evolution of ALEs in genes involved in DNA damage
response and cell cycle provides an additional layer of gene
expression regulation in complex processes and organisms.
Methods
Cell culture and transfection. MCF-7 cells from ATCC grown in DMEM sup-
plemented with 10% of FBS were plated at 50–75% of conﬂuence, 48 h before drug
treatments. All treatments with DOXO (2 mgml 1 in water), CPT (1 mM in 0.1%
DMSO) and vehicle (0.1% DMSO) were done for 6 h unless otherwise stated. Cells
were transfected for 48 h with siRNAs (sequences in Supplementary Table 1) at a
ﬁnal concentration of 25 nM by reverse transfection using Lipofectamine RNAi-
Max (Invitrogen). Cells were transfected with GFP-CENPN isoform constructs
in pEGFP-C1 vector using Lipofectamine LTX reagent (Invitrogen) for 24 h.
The GFP-CENPN-pA12 and DC-ter constructs were a generous gift from
A.F. Straight30.
FACS analysis. For FACS analysis, cells were ﬁxed in 70% ethanol at 4 C, DNA
was stained for 15min with 20 mgml 1 propidium iodide and 1mgml 1 RNase A
in PBS at room temperature, and FACS data were analysed using the Mod Fit
software.
RNA preparation and RT–(q)PCR. To prepare nuclear RNA, cells were lysed for
5min in 10mM Tris–HCl (pH7.8); 140mM NaCl, 1.5mM MgCl2, 10mM EDTA
and 0.5% NP40 supplemented with RNase inhibitors (Invitrogen) and nuclei were
pelleted at low speed. Total and nuclear RNA were extracted using TriPURE
(Roche) and 1 ml of Glycoblue (Ambion) was added for RNA precipitation. Nuclear
RNA was treated with DNase I (DNAfree, Ambion). Reverse transcription (RT)
was performed using M-MLV (Invitrogen) and random primers. PCR was per-
formed using GoTaq (Promega). qPCR was performed using Master SYBR Green I
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(Roche) on a Roche LightCycler. Primer sequences are given in Supplementary
Table 2. Full scans of gels are provided in Supplementary Fig. 7.
Western blot. Total protein extracts were prepared in 50mM Tris HCl (pH8),
400mM NaCl, 5mM EDTA, 1% NP40, 0.2% SDS and 1mM DTT supplemented
with protease inhibitors. Following SDS-PAGE analysis, immunoblotting was done
with antibodies against HuR or Actin. Antibodies are described in Supplementary
Table 3. Full scans of blots are provided in Supplementary Fig. 8.
Immunoﬂuorescence. Cells grown on glass coverslips were ﬁxed with 4% paraf-
ormaldehyde for 5min, washed with PBS/20mM glycine, permeabilized with 0.5%
Triton X-100 in PBS for 5min, washed with PBS/20mM glycine, incubated with
antibodies against CENPA, CENPH (generous gift of S.T. Liu59) or HuR in PBS/3%
FBS for 1 h at room temperature, washed with PBS/20mM glycine, and incubated
for 30min at room temperature with appropriate secondary antibodies: anti-mouse
IgG (Hþ L) Alexa Fluor 555, anti-rat IgG (Hþ L) Alexa Fluor 488, or anti-mouse
IgG (Hþ L) Alexa Fluor 488 (1/1,000, Invitrogen). Cells were incubated in
DNA staining solution (0.5 mgml 1 Hoechst 33258 in PBS) for 5min. Coverslips
were washed and mounted using ﬂuoromount medium and sealed. Image
acquisition was performed using Zeiss 780 and Leica SP5 confocal microscopes.
Antibodies are described in Supplementary Table 3.
Chromatin and RNA immunoprecipitation. For chromatin immunoprecipitation,
1.5 million cells were crosslinked with 1% (v/v) formaldehyde before lysis in 50mM
Tris–HCl (pH 7.5), 150mM KCl, 5mM EDTA, 1% NP40, 0.1% SDS and 0.5%
sodium deoxycholate supplemented with protease and phosphatase inhibitors
(Roche). DNA was sonicated for 14 cycles (30 s High, 30 s wait) using a Bioruptor
(Diagenode). After spinning, lysates were diluted 1/3 in lysis buffer without SDS
and immunoprecipitated overnight with an antibody against Pol-II (CTD4H8,
Upstate, 3 mgml 1) or control mouse immunoglobulins (Santa Cruz) that were
pre-incubated with Dynabeads G (Invitrogen). After ﬁve washes in immunopre-
cipitation buffer and two washes in 10mM Tris–HCl (pH 7.5), 1mM EDTA, bead/
immunoprecipitate complexes were resuspended in 50mM Tris–HCl (pH 7.5),
5mM EDTA, 10mM DTT, 1% SDS, reverse-crosslinked at 65 C overnight and
treated with 20 mg of proteinase K. DNA was puriﬁed using Nucleospin columns
(Macherey Nagel) and analysed by qPCR. For each condition, immunoprecipitate
was compared with input (aliquot of DNA before immunoprecipitation). For RNA
immunoprecipitation, 3 millions cells were lysed in 25mM Tris–HCl (pH 7.5),
150mM KCl, 2mM EDTA and 0.5% NP40 0.5mM DTT supplemented with
protease, phosphatase and RNase inhibitors (Invitrogen). RNA was immunopre-
cipitated in lysis buffer with an antibody against HuR (3A2, Santa Cruz, 6 mgml 1)
or control mouse immunoglobulins that were pre-incubated with Dynabeads G.
After ﬁve washes in 50mM Tris–HCl (pH7.5), 150mM KCl, 0.5% NP40 and two
washes in 10mM Tris–HCl (pH 7.5), 1mM EDTA, bead/immunoprecipitate
complexes were resuspended in 50mM Tris–HCl (pH 7.5), 5mM EDTA, 10mM
DTT and 1% SDS supplemented with RNase inhibitor, and reverse-crosslinked
for an hour at 70 C. RNA was puriﬁed from immunoprecipitates and input
samples using TriPURE (Roche), treated with DNase I (Ambion) and analysed
by RT–qPCR.
Exon-array analyses. One microgram of total RNA was processed according to
the manufacturer’s instructions and hybridized to GeneChip Human Exon 1.0 ST
arrays (Affymetrix). The experiments, from cell treatment to array hybridization,
were performed three times. Exon-array data were analysed with Expression
Console (Affymetrix) to perform quality assessment and normalized using quintile
normalization. Background correction and probe selection were performed as
previously described, using exon annotation from the Faster DB database22,60
(http://fasterdb.lyon.unicancer.fr/). Global gene regulation was calculated based on
exonic probes from the whole gene. The splicing index method corresponds to a
comparison of gene-normalized exon intensity values between two analysed
experimental conditions. We also developed a method comparing internal ALEs
with the following exon. Exon-array data of each regulated exon were visualized in
gene context using the exon-array visualization tool of Faster DB (Elexir), allowing
to eliminate false positives and to classify exonic regulations into different types
(ALE, and so on). For CPT, a top-list of 223 exons regulated by 42.2-fold
(Supplementary Data 3) was used for comparison with DOXO. Functional gene
annotation analyses were done using the DAVID software61,62, using the human
genome as a reference.
Bio-informatic analysis of ALEs. Two main types of internal ALEs exist: ‘skipped
ALEs’ are either skipped or included as terminal exons, whereas ‘composite ALEs’
can be included as either short internal exons or long terminal exons7,8. For bio-
informatic analyses (Figs 2b–e and 5g,h), we compared DOXO-repressed internal
skipped ALEs (n¼ 62) with other internal skipped ALEs genome-wide (obtained
from Genbank cDNAs). In Fig. 2b, only genes with at least six cDNAs ending at
either ALE were analysed. In Fig. 2c, only genes with both ALEs detected in
untreated cells were analysed. In Fig. 2d,e, ambiguous cases were discarded. Exon
conservation (Fig. 2e,f) was analysed using Multiz Alignment of 46 Vertebrates63 in
the UCSC genome browser. CLIP-Seq data were analysed by mapping reads to
DOXO-regulated and control internal skipped ALEs. To look for correlation
between expression of DOXO-regulated ALEs and splicing/ polyadenylation
factors, we used a publicly available exon-array data set on 60 human cell lines
(ENCODE)34. In each cell line, we calculated gene-normalized expression of
89 DOXO-stimulated last ALEs and the expression level of 163 splicing/
polyadenylation factors (list available upon request). For each couple (ALE, factor),
a Spearman correlation test was run; (anti-)correlation required that rho factor be
more than rho min and P value beo0.05. We found 21 factors that anti-correlated
(and none that correlated) with the inclusion rate of a signiﬁcant number of
DOXO-stimulated last ALEs (including CENPN’s).
Statistical analyses. For each experimental analysis, including exon-array data
analyses, at least three independent experiments were performed. In ﬁgures, error
bars represent the s.e.m., which is the s.d. divided by the square root of sample
number. For all statistical analyses performed in this study, tests were considered
signiﬁcant for Pr0.05. For exon-array analyses, a Student’s paired t-test was used.
The statistical tests used in other bio-informatic analyses are indicated in ﬁgure
legends.
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